Urinary Metabolomic Profiling Reveals Biological Pathways and Predictive Signatures Associated with Childhood Asthma

Abstract

Background

Despite considerable efforts, the pathogenic mechanisms of asthma are still incompletely understood, due to its heterogeneous nature. However, metabolomics can offer a global view of a biological system, making it a valuable tool for further elucidation of mechanisms and biomarker discovery in asthma.

Methods

GC-MS–based metabolomic analysis was conducted for comparison of urine metabolic profiles between asthmatic children (n=30) and healthy controls (n=30).

Results

An orthogonal projections to latent structures discriminant–analysis model revealed a clear separation of the asthma and control groups (R²_x=0.137, R²_y=0.947, Q²=0.82). A total of 20 differential metabolites were identified as discriminant factors, of which eleven were significantly increased and nine decreased in the asthma group compared to the control group. Pathway-enrichment analysis based on these differential metabolites indicated that sphingolipid metabolism, protein biosynthesis, and citric acid cycle were strongly associated with asthma. Among the identified metabolites, 2-hydroxybutanoic acid showed excellent discriminatory performance for distinguishing asthma from healthy controls, with an AUC of 0.969.

Conclusion

Our study revealed significant changes in the urine metabolome of asthma patients. Several perturbed pathways (eg, sphingolipid metabolism and citric acid cycle) may be related to asthma pathogenesis, and 2-hydroxybutanoic acid could serve as a potential biomarker for asthma diagnosis.

Introduction

Asthma is the most common chronic inflammatory airway disease in childhood, and is characterized by airway hyperresponsiveness coupled with reversible airway obstruction.¹ High prevalence of asthma in children is found in both high-income countries and low- and middle-income countries.¹ For instance, asthma affects approximately 6 million children in the US.² As one of the most asthma-afflicted countries, China has nearly 30 million asthmatics, 10 million of which are children.³ Also, the Chinese National Cooperative Group on Childhood Asthma reported the prevalence of asthma in children aged 0–14 years in China was 0.09%–2.60% in 1990, 0.52%–3.34% in 2000, and 0.42%–5.73% in 2010, with the national average being 0.91%, 1.54%, and 2.32%, respectively, indicating the increasing number of pediatric asthma patients over the last few decades.⁴ As a result, childhood asthma imposes a heavy burden on both society and individual families, due to increased hospital visits, health-care costs, and parental absence from work, compared to asthma in adults.^1,5,6 Despite considerable advances in diagnosis and long-term management, asthma still accounts for 0–0.7 per 100,000 deaths in children globally and remains a serious public health concern.¹

Currently, inhaled and oral corticosteroids, inhaled short-acting and long-acting β₂ agonists, and leukotriene-receptor antagonists are commonly used as therapeutic drugs for asthma;⁷ however, some patients show completely refractory responses to these treatments.^8,9 Even worse, side effects, including osteoporosis, immunosuppression, mood changes, and hypothalamic–pituitary–adrenal axis suppression, have been found to be associated with corticosteroid intake at high doses or prolonged use of inhaled corticosteroids.¹⁰ As a multifaceted disease, asthma is influenced by interactions among multiple genetic, epigenetic, and environmental factors.¹¹ Although a number of genetic determinants have been identified, incomplete understanding of molecular determinants as mediators of asthma pathogenesis are major impediments to asthma prevention and treatment.^12,13 Given the heterogeneity of underlying pathogenesis, early diagnosis and management of asthma are considerably more difficult in asthmatic children, as they undergo rapid biological, developmental, and psychosocial changes in a relatively short period. As such, these issues underscore the crucial need to better understand childhood asthma by identifying potential diagnostic biomarkers/therapeutic targets and illustrating pathophysiological mechanisms.

In recent years, metabolomics, which systematically analyzes the global collection of endogenous small-molecule metabolites (eg, amino acids, lipids, carbohydrates, nucleotides, and organic acids) in biological specimens (eg, biofluid, cells, and tissue), provides a comprehensive assessment of biological processes (eg, redox balance, oxidative stress, signaling transduction, apoptosis, and inflammation).¹⁴ For instance, a high-resolution metabolomic study conducted by Khan et al showed that L-homocysteine sulfinic acid and cysteic acid along with carnitine could serve as promising noninvasive biomarkers for early acute myocardial infarction detection.¹⁵ Global metabolomic analysis showed nitrogen metabolism and its components (glycine, taurine, and phenylalanine) was a potential effector of the earliest stages of type 2 diabetes pathophysiology,16 indicating metabolomics can be employed in biological studies or biomarker-screening studies. Similarly, several studies have been performed for asthma to identify novel biomarkers and altered pathways and have contributed to better understanding of asthma pathogenesis.^17–25 As a result, a variety of metabolic pathways (including glycine, serine, and threonine metabolism, N-acylethanolamine and N-acyltransferase pathways, and glycerophospholipid, retinol,and sphingolipid metabolism) and biological molecules (such as methionine, glutamine, and acetate) have been found to be involved in the progression of asthma.^11,17–25 However, most of these studies were conducted in animal models or adult patients. Furthermore, samples used were usually sera or bronchoalveolar lavage fluid. On the other hand, urine-based biomarkers are especially appealing in children,^23–25 as urine collection is noninvasive, easily accessible, abundant, stable, and comprehensive in metabolite composition.

Taking into consideration these issues, we aimed to further systematically study metabolic perturbance in asthmatic children by applying GC-MS–based metabolomic analysis to urine samples in the current study. More specifically, our findings not only identify potential biomarkers of interest and provide pathway and mechanistic information but also provide important data complementing previous studies.

Methods

Study Population

Thirty children with asthma and 30 age- and sex-matched healthy controls were recruited from Children’s Hospital, Zhejiang University School of Medicine between March 2015 and August 2015. Asthma diagnosis was confirmed by pediatric respiratory physicians based on clinical history, eg, recurrent cough, recurrent wheeze, shortness of breath, chest tightness, and evidence of reversible airway obstruction of ≥12% increase of forced expiratory volume in 1 second (FEV₁) after bronchodilator inhalation, according to Global Initiative for Asthma guidelines.²⁶ Asthmatic subjects with normal lung function free from asthma exacerbations for at least 3 months were considered stable asthmatic patients. Normal lung function was indicated by FEV₁, forced vital capacity (FVC), peak expiratory flow ≥80% predicted, and bronchial obstruction FEV₁/FVC <90%.²⁶ All asthmatic subjects had used inhaled corticosteroids as a maintenance medication, and all were in stable condition. All asthmatic medications were stopped for at least 3 days before sampling to minimize possible drug effects on urine-metabolite levels. Healthy controls had no history of chronic respiratory condition, allergic diseases, or any other diseases that might influence the results. None of the participants had had acute airway infection in 6 weeks, or were prescribed a particular diet or food deprivation before sampling. At recruitment, children underwent routine blood tests, lung-function assessment and total IgE determination. Meanwhile,demographic and atopic-index data were collected. The Ethics Committee of the Children’s Hospital, Zhejiang University School of Medicine approved the study, and all parents provided written informed consent prior to sample and data collection. All methods were conducted in accordance with the principles of the Declaration of Helsinki.

Urine-Sample Collection and Preparation

Early-morning midstream-urine specimens were collected following overnight fasting, centrifuged at 3,000 rpm for 10 minutes at 4°C to remove debris, and then the supernatants were kept at −80°C until analysis. After being thawed at room temperature and centrifuged at 10,000 rpm for 5 minutes, 200 μL urine samples were treated with 20 μL urease to degrade the urea at 37°C for 60 minutes. Then, 40 μL 0.1 mg/mL L-2-chlorophenylalanine (Hengbai Biotech, Shanghai, China) was added as an internal standard and vortex-mixed for 30 seconds. Subsequently, 600 μL methanol was added to this solution, followed by centrifugation at 13,000 rpm for 10 minutes at 4°C to precipitate the protein. Thereafter, the supernatant was transferred to a new tube and dried under a stream of N₂ gas. Before analysis, the dried metabolic extracts were dissolved in 30 μL methoxyamine solution (20 mg/mL in pyridine) at 37°C for 90 minutes. Later, 30 μL methyl-N-trimethylsilyltrifluoroacetamide with 1% chlorotrimethylsilane was added for trimethylsilylation for 60 minutes at 65°C. After derivatization, the supernatant was subjected to GC-MS analysis. Meanwhile, quality control (QC) samples, used for monitoring the repeatability, stability, and reliability of the analytical method, were prepared by mixing equal volumes (10 μL) of urine samples from all subjects before sample processing. The pooled QC sample was pretreated as aforementioned for experimental samples. Each QC sample was then injected every ten experimental samples throughout the whole assay.

GC-MS Analysis

A 7890 GC system (Agilent Technologies, Santa Clara, CA, USA) coupled with a Pegasus HT time-of-flight mass spectrometer (Leco, St Joseph, MI, USA) was used to analyze the derivative samples. Samples (1 µL) were injected in splitless mode with helium as the carrier gas at a constant flow rate of 1 mL/min, and then separated with an HP5 MS fused-silica capillary column (30 m × 0.25 mm × 0.25 μm; Agilent). The initial column temperature was set at 50°C for 1 minute, raised to 330°C at a rate of 10°C/minute, and then held at 330°C for 5 minutes. Temperatures for the inlet, transfer line, and ion source were 280°C, 280°C, and 250°C, respectively. Ionization was achieved in electron-impact mode at 70 eV. MS data were obtained in full-scan mode across a mass:charge ratio of 30–600 at a rate of 20 spectra per second after a solvent delay of 366 seconds.

Data Processing

Chroma TOF4.3X (Leco) and the Leco-Fiehn Rtx5 database were employed for preprocessing the raw data obtained from GC-MS, including raw peak extraction, data baseline filtering and calibration, peak alignment, deconvolution analysis, peak identification, and integration of the peak area.²⁷ The retention index was used to identify the peak, and index tolerance was 5,000. Metabolites were identified by referring their mass spectra and retention indices of peaks to to the Leco-Fiehn Metabolomics Library. If the similarity value generated from the library were >700, it indicated the metabolite identification was reliable.²⁷ The metabolic features detected in less than half the QC samples were removed. Additionally, missing values of raw data were filled by half the minimum value. The metabolites were left using interquartile-range denoising, and data analysis was accomplished using internal-standard normalization.²⁸ Then, the resultant data of peak numbers, sample names, and normalized peak areas were imported to Simca version 14.0 (Umetrics, Umea, Sweden) for principal-component analysis (PCA) and orthogonal projections to latent structure–discriminant analysis (OPLS-DA) to observe metabolic variations between samples. In detail, PCA was used to display the overall difference, while OPLS-DA was used to verify the model and visualize discrimination between groups.²⁹ Significantly different metabolites were screened by variable importance for projection (VIP) values >1 and p<0.05.²⁹ For detecting the diagnostic capacity of the identified panel, receiver-operating characteristic (ROC) curves and area under the ROC curve (AUC) were computed by R package version 3.1.0.³⁰

Pathway analysis and functional enrichment analysis of metabolites was done with MetaboAnalyst 3.0, which is online software with predictive ability mapped to the Kyoto Encyclopedia of Genes and Genomes metabolic pathway database.³¹ All identified pathways were shown according to p-values from pathway-enrichment analysis and pathway-impact values from pathway-topology analysis.³¹ The criteria applied to select significantly altered metabolic pathways were p<0.05 and impact >0.

Statistical Analysis

SPSS version 23.0 was used for statistical analysis of the baseline characteristics of the study subjects. Categorical variables are represented as numbers (percentages) and were analyzed with χ² tests. Continuous normal–distribution variables are expressed as means ± SD and were analyzed with Student’s t-test, while continuous abnormal-distribution variables are expressed as median (25th–75th percentile) and analyzed with Mann–Whitney U test. Results were considered statistically significant at p<0.05.

Results

Population Characteristics

A total of 60 children were enrolled in this study: 30 asthmatics and 30 healthy controls. Comparison of baseline characteristics of children with asthma and healthy controls is presented in Table 1. There were significant differences in eosinophil percentage, eosinophil count, FVC (% predicted), FEV₁ (% predicted), peak expiratory flow (% predicted), total IgE levels, and atopic indices (including pollen, cold air, and mite sensitization) between children with asthma and healthy controls. There were no differences in age, sex, height, weight, BMI, white blood–cell counts, food sensitization, or FEV₁/FVC between the groups.

Table 1.

Baseline Characteristics of the 60 Children Investigated in this Study

	Asthma (n=30)	Controls (n=30)	p
Age (years)	8 (7–11)	9 (8–10.25)	0.192
Sex (male/female)	20/10	20/10	1
Height (cm)	134.60±16.25	132.39±12.98	0.700
Weight (kg)	31.41±10.17	32.54±11.77	0.575
BMI (kg/m2)	16.52 (15.55–18.49)	15.67 (14.88–21.64)	0.981
Routine blood tests
WBC count (×109/L)	8.91±3.29	8.97±2.37	0.937
E (%)	3.50 (2.70–5.13)	1.80 (1.05–2.48)	<0.001
EC (×107/L)	31.98 (16.61–46.83)	13.07 (9.16–22.37)	<0.001
Atopic indices
Pollen sensitization	13 (43.3%)	0 (0)	<0.001
Cold-air sensitization	25 (83.3%)	2 (6.7%)	<0.001
Mite sensitization	30 (100%)	1 (3.3%)	<0.001
Food sensitization	7 (23.3%)	3 (10%)	0.166
IgE (IU/mL)	365.50 (229.50–647.50)	27.40 (18.50–68.85)	<0.001
Lung-function tests
FVC (% predicted)	88.40 (83.58–93.60)	103.15 (98.98–110.95)	<0.001
FEV1 (% predicted)	94.85 (91.90–100.35)	107.60 (105.35–120.65)	<0.001
FEV1/FVC (%)	91.07(89.92–94.87)	91.29 (88.37–92.94)	0.375
PEF (% predicted)	88.79±12.94	103.35±15.44	<0.001

Notes: Data shown are means ± SD, median (25th–75th percentile), and n (%) of patients as appropriate.

Abbreviations: BMI, body-mass index; WBC, white blood cell; E, eosinophil; EC, eosinophil count; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 second; PEF, peak expiratory flow.

Metabolic Profiling

After GC-MS data processing, 333 peaks were detected (Supplementary Dataset 1). After the missing raw data had been filled by half the minimum value, 232 metabolites (Supplementary Dataset 2) were finally selected through interquartile-range denoising and internal standard normalization.^27,28

Initially, PCA was performed to show the distribution of the original data. As shown in the score plots of PCA (Figure 1 and Supplementary Figure 1), although the R² and Q² values generated from the PCA model appeared to be low (R²_x=0.152, Q²=0.0396), a separation trend of samples between the two groups was observed. Subsequently, OPLS-DA was applied to further improve group separation and get a better understanding of variables responsible for the classification. The score plot of the OPLS-DA model demonstrated that the asthma and control groups were fully separated (R²_x=0.137, R²_y=0.947, Q²=0.82; Figure 2A), implying robust metabolic differences between the asthma and control groups. Through a permutation test repeated 200 times, Q² and R² values were found to be higher than their original values (Figure 2B), suggesting goodness of fit and better predictive capability for the OPLS-DA models.

Figure 1.

PCA model generated based on GC-MS analysis of urine samples from asthmatic and healthy subjects. The _X- (PC1) and y-axes (PC2) indicate the first and second principal components, respectively.

Figure 2.

OPLS-DA plots with corresponding permutation-test plot obtained from GC-MS metabolite profiles of asthmatic and healthy subjects. (A) Score plot of OPLS-DA model showing clear separation of asthma patients from healthy subjects. The x- (t[1]P) and y- (t[1]O) axes indicate predictive and orthogonal directions, respectively. (B) Permutation test (200×)of the OPLD-DA model showing corresponding permuted values (bottom left) as significantly lower than original R² and Q² values (top right), demonstrating the robustness of the OPLS-DA model. R² and Q² indicate interpretability and predictability, respectively.

Potential Metabolite-Biomarker Identification

According to the ranking of VIPs from the OPLS-DA models, 20 metabolites were considered associated with asthma (with VIP >1 and p<0.05): five amino acids, three fatty acids, four organic acids, four sugars, and four aromatic compounds (Table 2). Levels of eleven metabolites — L-allothreonine 1, stearic acid, succinic acid, 2-hydroxybutanoic acid, azelaic acid, gentiobiose 2, tyramine, leucine, D-altrose 1, D-erythrosphingosine 1, and citraconic acid 4 — were significantly higher in urine samples from asthmatic patients than healthy controls. In contrast, levels of nine metabolites — valine, uric acid, methionine 1, 3,4-dihydroxycinnamic acid, purine riboside, malonic acid 1, cysteine, erythrose 1, and lactamide 1 — were significantly lower in the urine of asthmatic patients than control subjects.

Table 2.

Identification of Differentially Abundant Metabolites in Urine between Asthmatic and Healthy Subjects

	Peak	Similarity	RT	Count	Mass	MEAN Case	MEAN Control	VIP	pvalue	qvalue	Foldchange	Log_foldchange
Upward
241	L-allothreonine 1	920.07692	11.4128	27	57	6.51E-03	2.97E-10	2.02E+00	8.24E-06	1.23E-04	2.19E+07	2.44E+01
803	Stearic acid	888.7037	20.5262	27	117	9.58E-04	2.97E-10	2.08E+00	7.68E-06	1.17E-04	3.22E+06	2.16E+01
188	Succinic acid	852.18421	10.497	38	147	1.86E-02	2.79E-03	1.80E+00	9.38E-05	9.10E-04	6.67E+00	2.74E+00
35	2-hydroxybutanoic acid	844.625	6.98317	41	205	3.86E-04	2.23E-05	2.61E+00	5.40E-14	4.91E-12	1.73E+01	4.12E+00
561	Azelaic acid	799.24138	16.2649	29	55	1.39E-03	2.97E-10	1.86E+00	1.13E-04	1.05E-03	4.68E+06	2.22E+01
924	Gentiobiose 2	723.17857	25.0148	28	204	1.77E-04	2.97E-10	1.86E+00	5.05E-05	5.39E-04	5.96E+05	1.92E+01
647	Tyramine	702.08	17.4788	25	174	6.55E-04	2.97E-10	1.93E+00	2.40E-05	2.87E-04	2.21E+06	2.11E+01
149	Leucine	699.1875	9.88965	33	158	2.09E-03	5.59E-04	1.30E+00	2.21E-03	1.47E-02	3.75E+00	1.91E+00
618	D-altrose 1	599.33333	17.1239	33	274	5.66E-04	4.63E-05	1.81E+00	2.82E-05	3.24E-04	1.22E+01	3.61E+00
850	D-erythro-sphingosine 1	569.69231	22.1272	33	204	7.83E-05	1.35E-05	1.53E+00	1.92E-03	1.31E-02	5.79E+00	2.53E+00
226	Citraconic acid 4	464.30303	11.1181	35	160	2.75E-04	5.34E-05	1.30E+00	8.25E-03	3.94E-02	5.16E+00	2.37E+00
Downward
116	Valine	906.39706	9.11453	69	144	2.52E-03	3.42E-03	1.39E+00	1.01E-02	4.55E-02	7.37E-01	−4.41E-01
750	Uric acid	900.03333	19.2648	60	442	2.29E-02	3.20E-02	1.10E+00	2.60E-02	9.11E-02	7.14E-01	−4.85E-01
358	Methionine 1	720.01639	13.1243	62	176	1.79E-04	3.04E-04	1.42E+00	6.92E-03	3.45E-02	5.88E-01	−7.66E-01
768	3,4-dihydroxycinnamic acid	713.37209	19.5959	43	219	1.59E-04	5.38E-04	1.17E+00	2.75E-02	9.50E-02	2.96E-01	−1.76E+00
834	Purine riboside	649.93333	21.647	69	262	8.98E-05	1.16E-04	1.48E+00	4.40E-02	1.29E-01	7.75E-01	−3.67E-01
106	Malonic acid 1	566.30357	8.85469	64	147	3.10E-03	5.06E-03	1.34E+00	8.61E-04	6.74E-03	6.13E-01	−7.07E-01
811	Cystine	545.83333	20.8769	56	73	1.85E-03	3.59E-03	1.04E+00	2.68E-02	9.32E-02	5.15E-01	−9.57E-01
304	Erythrose 1	525.84375	12.2841	65	350	3.52E-03	8.17E-03	1.21E+00	9.66E-03	4.42E-02	4.30E-01	−1.22E+00
77	Lactamide 1	485.86667	8.18238	61	104	3.75E-04	8.39E-04	1.35E+00	3.40E-03	2.02E-02	4.47E-01	−1.16E+00

Note: Fold change: asthma versus control.

To further evaluate the diagnostic efficacy of the aforementioned metabolites, ROC curves were constructed and AUCs calculated. As shown in Supplementary Table 1, only 2-hydroxybutanoic acid showed excellent accuracy with AUC of 0.969, sensitivity 96.2%, and specificity of 100% (Figure 3), while ten metabolites showed moderate accuracy (AUC 0.7–0.8) and the remaining nine metabolites showed poor accuracy (AUC <0.7).

Figure 3.

ROC analysis of 2-hydroxybutanoic acid for distinguishing asthma patients from healthy controls (AUC=0.969).

Construction of Metabolic Pathways Based on Differential Metabolites

To further illustrate the underlying meaning of the altered metabolic products, the 20 differential metabolites were imported into MetaboAnalyst 3.0 to conduct pathway and functional enrichment analysis. As shown in Figure 4A and Supplementary Table 2, 32 perturbed metabolic pathways were identified, among which ten were significantly perturbed in asthma patients compared with healthy controls (p<0.05, impact >0). Within these pathways, sphingolipid metabolism (p=0.0003, impact 0.103), citrate cycle (TCA cycle) (p=0.002, impact 0.075), and valine, leucine, and isoleucine biosynthesis (p=0.005, impact 0.034) pathways were highlighted as targets for investigating pathological mechanisms underlying childhood asthma. Functional enrichment analysis revealed that the top-three pathways associated with asthma were sphingolipid metabolism, protein biosynthesis, and citric acid cycle (Figure 4B, Supplementary Table 3).

Figure 4.

Metabolic pathway analysis of differential metabolites identified from asthma patients compared with healthy controls. (A) Significantly changed pathways based on enrichment and topology analyses: sphingolipid metabolism (a), citrate cycle (b), valine, leucine, and isoleucine biosynthesis (c), propanoate metabolism (d), aminoacyl–tRNA biosynthesis (e), tyrosine metabolism (f), glycine, serine, and threonine metabolism (g), glyoxylate and dicarboxylate metabolism (h), cysteine and methionine metabolism (i), and alanine, aspartate, and glutamate metabolism (j). (B) Functional enrichment analysis of pathways. Color depth and column length indicate degree of disturbance.

Discussion

Despite the clinical and public health concern of asthma, the molecular determinants involved in the pathophysiological processes of asthma are still not fully understood.³² Particularly, the pathogenesis of childhood asthma is different from adult asthma.⁵ Asthma onset starts early in life and can carry into adulthood.⁵ As terminal products downstream from genes and proteins, metabolites are inherently sensitive to subtle alteration in biological pathways. Therefore, metabolomic studies have been applied to discover biomarkers/therapeutic targets and reveal underlying mechanisms of various diseases.³³ Similarly, in the current study we provided an overview of metabolic changes in asthma during childhood based on a GC-MS metabolomic approach, which broadens our knowledge of pathobiological pathways involved in childhood asthma and sheds light on the prevention, diagnosis, and treatment of asthma at an early age. Moreover, asthma diagnosis relies on clinical manifestations and confirmed expiratory-airflow limitation, but symptoms and pulmonary function measurements may not always reflect the underlying airway inflammation and are insensitive to small variations in inflammatory status.^5,32 Indeed, asthmatic children enrolled in the present study were stable and had normal lung function. In other words, the 20 identified metabolites imply an inflammatory condition, which is a characteristic of asthma pathophysiology. Altogether, the major novel finding emerging from our study is the discovery of new molecules, which may pave the way for the development of effective asthma management and the study of metabolic pathways involved in childhood-asthma pathogenesis.

Several studies have also examined metabolic profiles for asthma by applying metabolomic approaches using different biofluids from either experimental asthma models or clinical samples, and some distinct metabolites were identified.^18–20 For instance, four eicosanoid-related metabolites identified from portable exhaled breath–condensate metabolomics were found to be related to asthmatic conditions.¹⁹ Pang et al reported 18 metabolites in the sera of asthma patients.¹⁸ Distinctive compartmental metabolic signatures have also been observed in bronchoalveolar lavage fluid, sera, and lung tissue in a murine model of house dust mite–induced asthma.²⁰ Although the identified metabolites vary from study to study, different study populations, experimental designs, biological samples, disease states, and metabolomic techniques used in these studies might all contribute to these differences. Still, these studies, including ours, could complement each other for in-depth illustration of the pathogenesis of asthma.

Although significant differences exist, common features can also be found among studies. For example, McGeachie et al showed that altered sphingolipid metabolism represented an underlying feature of both asthma control and cellular response to albuterol by integrating metabolomic, genomic, and methylation data.²¹ In addition, when we analyzed the metabolomic results from Comhair et al,²² sphingolipid metabolism was ranked second in pathway-enrichment analysis (Supplementary Figure 2). Furthermore, previous integrated omics analysis discovered that impaired lung function was associated with dysregulated sphingolipid metabolism in asthma.³⁴ Likewise, enrichment of sphingolipid metabolites is positively correlated with disease severity among infants with bronchiolitis, which is one of the risk factors for asthma development.^35,36 Taken together, these observations suggest a key role of dysregulated sphingolipid metabolism in the development of childhood asthma, which might serve as a novel therapeutic target for asthma. Indeed, in asthma mouse models inhibition of sphingosine kinase–attenuated airway inflammation has been demonstrated,^37,38 emphasizing the therapeutic potential of this pathway.

As one of the altered sphingolipids identified in our study, D-erythrosphingosine 1 is known to inhibit arachidonic acid release and prostaglandin F_2α formation in cells.³⁹ On the other hand, some lipid mediators (eg, cysteinyl leukotrienes) in asthma are produced from arachidonic acid.⁴⁰ Inflammatory factors produced during the development of asthma may simulate the requirement of energy.⁴¹ Interestingly, a prominent change in energy metabolism, eg, the TCA cycle, where most of the body’s energy is generated,⁴² has been observed in asthma patients (Figure 4). Notably, succinic acid (an intermediate compound in the TCA cycle) is the third–most enriched metabolite in asthma samples (Table 2). This is consistent with previous studies in which higher abundance of succinic acid in the urine or serum of asthmatic patients was reported.^11,43,44 Additionally, branched-chain amino acids, including valine, leucine, and isoleucine, showed changes in asthma patients. Of note, valine and leucine affect the TCA cycle through succinyl-CoA formation and acetyl-CoA formation, respectively. It was noted that methionine, a glucogenic amino acid and potential energy source, was decreased in the urine of asthma patients in our study. Collectively, our results provide evidence that asthma is tightly associated with abnormalities in energy metabolism, especially the TCA cycle.

We also report for the first time that levels of 2-hydroxybutanoic acid were significantly higher in the asthma group than healthy subjects (Table 2). The underlying biochemical mechanism may involve increased lipid oxidation and oxidative stress in asthma pathogenesis, because 2-hydroxybutanoic acid is produced from threonine and methionine catabolism, as well as glutathione metabolism.⁴⁵ It might also be related to the altered energy metabolism, as it has been reported that 2-hydroxybutanoic acid can alter the intracellular balance of acetyl-CoA, succinyl-CoA, and NAD, which are all important molecules in the TCA cycle.⁴⁶ We found that 2-hydroxybutanoic acid possessed the highest AUC (0.969) and was able to distinguish asthma from healthy controls (Figure 3) in the present study. This suggested 2-hydroxybutanoic acid might be of great importance as a biomarker in diagnosing asthma or monitoring asthma progression. Interestingly, 2-hydroxybutanoic acid has been shown to be a reliable marker for early-stage type 2 diabetes.⁴⁷ On the other hand, studies have shown that exogenous 2-hydroxybutanoic acid has therapeutic benefits against stress conditions, such as kidney injury,⁴⁸ depression,⁴⁹ Alzheimer’s disease, and atherosclerosis.⁵⁰ Further studies are warranted to discover the precise function of 2-hydroxybutanoic acid in asthma.

There are several limitations to our study. Firstly, this was a single-center study with a relatively small sample. Our results cannot be fully extrapolated to all asthmatic patients, as we recruited only pediatric patients with stable asthma. These results should be validated in a multicenter prospective and larger-scale study to evaluate our findings to discriminate asthma from healthy controls. Secondly, the biomarkers identified in the present study may not be specific for asthma. A new study comparing differential metabolites for asthma and other lung diseases (eg, cystic fibrosis and idiopathic pulmonary fibrosis) will help identify specific biomarkers for asthma. Thirdly, the mechanisms behind the relationship between asthma and differential metabolites remain to be elucidated. Further studies involving molecular/cellular biology and animal models are required to reveal potential pathological mechanisms of asthma comprehensively. Fourthly, we could not determine whether the metabolic changes in urine were the cause or consequence of asthma. Finally, given the pilot nature of this study, other possible confounding factors, such as ethnicity, passive smoking, lifestyle, and diet, were not taken into consideration. Altogether, it is still a great challenge to obtain systematic metabolome changes, because of complexity and individual factors. Further investigations are still necessary to translate metabolomics into clinical practice.

In summary, we observed metabolic dysregulation in urine samples of asthma patients. Sphingolipid metabolism and energy metabolism (TCA cycle) were the top-two altered pathways, and might be involved in the pathogenesis of asthma. Moreover, 2-hydroxybutanoic acid displayed good diagnostic performance in distinguishing asthma patients from healthy individuals.

Funding Statement

The work was supported by grants from the National Natural Science Foundation of China (31971138), Education Department Project of Zhejiang Province (Y201534178), and Zhejiang Provincial Natural Science Foundation (LQ20H190006).

Abbreviations

ROC, receiver-operating characteristic; GC-MS, gas chromatography-mass spectrometry; AUC, area under the ROC curve; PCA, principal-component analysis; OPLS-DA, orthogonal projections to latent structure–discriminant analysis; VIP, variable importance for projection.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval to the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors declare that they have no conflict of interests.